India, July 23 2025 ( TGN )- Today, Apollo Hospitals and Siemens Healthineers are proud to announce a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes—from early detection and risk stratification to monitoring intervention and therapy response.
The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, focusing on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes.
As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Prevalence ranges from 9% to 32%, higher among those who are overweight, obese, or have diabetes. NFHS-4 (2015-2016) reports 18-20% of adults are overweight/obese and 3-8% have abnormal blood sugar. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death.
Dr. Sangita Reddy, Joint Managing Director – Apollo Hospitals said, “At Apollo, we believe that the future of healthcare lies at the intersection of clinical excellence and cutting-edge technology anchored in patient centricity. Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD may be underestimated that poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies. AI-driven disease progression models shall play a pivotal role in early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. This model shall also facilitate precision population health strategies and clinical decision support across care settings. This partnership also reflects Apollo’s pioneering vision to embed intelligent systems across the clinical spectrum that predict faster, more accurate diagnoses and proactive patient management.”
“Liver disease is a growing health concern in India; it’s crucial to prioritize early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend. We believe that advanced technologies will aid timely and precise diagnosis, leading to better disease management and improving the quality of life for patients. Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership”- said Hariharan Subramanian, Managing Director, Siemens Healthcare, Private Limited.
Following the 2024 Memorandum of Understanding, the Master Research Agreement (MRA) was formalized in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the MRA Addendum was held on July 23, 2025, in Hyderabad, marking a significant milestone in this partnership.
About Apollo Hospitals: Apollo revolutionised healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world’s largest integrated healthcare platform with over 10,400 beds across 74 hospitals, 6,600+ pharmacies, 264 clinics, 2,182 diagnostic centres, and 800+ telemedicine centres. It is one of the world’s leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo’s 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.
Siemens Healthineers in India has a countrywide sales network and round-the-clock service set-up, two manufacturing facilities at Vadodara for Diagnostics and at Bengaluru for Medical Imaging Products, backed by a state-of-the-art R&D center as well as a global software development center at Bengaluru. With over 7000 employees across the nation, we are playing a significant role in transforming care delivery in India and supporting healthcare providers across the entire range of patient care – from prevention and early detection to diagnosis and on to treatment and aftercare. Further information is available at www.siemens-healthineers.co.in
